Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

por Fioretto, Paola, Stefansson, Bergur V., Johnsson, Eva, Cain, Valerie A., Sjöström, C. David
Publicado 2016

A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study

por Welty, Francine K., Lewis, Sandra J., Friday, Karen E., Cain, Valerie A., Anzalone, Deborah A.
Publicado 2016

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

por Dekkers, Claire C J, Wheeler, David C, Sjöström, C David, Stefansson, Bergur V, Cain, Valerie, Heerspink, Hiddo J L
Publicado 2018

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

por Dekkers, Claire C J, Wheeler, David C, Sjöström, C David, Stefansson, Bergur V, Cain, Valerie, Heerspink, Hiddo J L
Publicado 2018

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

por Dekkers, Claire C. J., Sjöström, C. David, Greasley, Peter J., Cain, Valerie, Boulton, David W., Heerspink, Hiddo J. L.
Publicado 2019

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers

por Heerspink, Hiddo J. L., Sjöström, C. David, Inzucchi, Silvio E., Hallow, Melissa K., Cain, Valerie A., Rossing, Peter, Stefansson, Bergur V., Sartipy, Peter
Publicado 2018

Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline

por Stefánsson, Bergur V., Heerspink, Hiddo J.L., Wheeler, David C., Sjöström, C. David, Greasley, Peter J., Sartipy, Peter, Cain, Valerie, Correa-Rotter, Ricardo
Publicado 2021

The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis

por Scholtes, Rosalie A., van Raalte, Daniël H., Correa‐Rotter, Ricardo, Toto, Robert D., Heerspink, Hiddo J. L., Cain, Valerie, Sjöström, C. David, Sartipy, Peter, Stefánsson, Bergur V.
Publicado 2019